SAMHSA & FDA Dear Colleague Letter Regarding Medication First Model For Opioid Addiction Treatment

On May 9, 2023, the Substance Abuse and Mental Health Services Administration (SAMSHA) and the U.S. Food and Drug Administration (FDA) published this "dear colleague" letter regarding the Medication First Model for opioid addiction treatment. This letter emphasizes the two entities' commitment to addressing the "overdose epidemic" through the provision of person-centered care and reducing barriers to accessing evidence-based treatments for addiction . . .